The phase II COCOON trial reported interim results showing proactive skincare reduced dermatologic toxicity by 50% in patients with EGFR-mutant non-small cell lung cancer (NSCLC) receiving frontline treatment. The trial evaluates supportive-care interventions designed to lower treatment-related adverse events that can lead to dose modifications or discontinuations. Led by investigators including Bishal Tiwari at Nassau University Medical Center, COCOON centers on dermatologic adverse events as a measurable endpoint in a setting where EGFR-targeted therapies commonly drive skin toxicity. The results strengthen the evidence base for routine toxicity prevention approaches in EGFR-mutant populations and could influence how oncology supportive care protocols are standardized.